鸡传染性法氏囊病灭活苗与基因工程亚单位疫苗免疫效果比较

应用SPF鸡分别比较研究了鸡传染性法氏囊病组织灭活苗和基因工程亚单位疫苗接种后的免疫效果,并用中等毒力毒株D78株攻毒后产生的免疫保护力。结果表明用于试验的灭活苗能够80％保护已经免疫的SPF鸡免于D78株人工感染造成的死亡,而基因工程亚单位相对效果较差,仅能保护20％。这说明在不受母源抗体干扰的情况下,灭活苗的免疫效果要优于基因工程亚单位疫苗。     

对几种血清Ⅰ型鸡马立克氏病疫苗的比较性评估

本文比较了4种血清Ⅰ型马立克氏病(MD)单价弱毒疫苗及其与血清Ⅱ型和Ⅲ型病毒混合多价疫苗在安全性及效力方面的差异。以0 2ml的剂量皮下接种1日龄母源抗体阳性的雏鸡。接种后5天 ,所有的疫苗接种鸡及对照鸡都用MD强毒株—Md 5或RB1/B株攻毒。血清Ⅰ型单价疫苗的保护指数由56至80以上不等。Ⅰ型毒 +HVT(Ⅲ型)疫苗的保护指数亦有很大的提高。用HVT +SB -1或HVT +301B/1与Ⅰ型毒组成的三价疫苗 ,其保护指数特别高。实验结果表明 ,三价疫苗用于因MD造成的高死亡率鸡群或被MD超强毒污染的鸡群会大有裨益。马立克氏病会引起感染鸡群的严重死亡和污染。MD可通过使用MD单价或含双价、三价的多价疫苗而得到控制。本研究的目的在于评估几种MDⅠ型不同毒株单价疫苗及多价疫苗对母源抗体阳性雏鸡的安全性和有效性     

IBDV地方野毒株不同毒源二价灭活油乳苗免疫效果的比较研究

对利用IBDV地方野毒株所制备的囊毒和胚毒二价灭活油乳苗免疫效果进行了比较研究。结果表明,所制备的囊毒灭活苗免疫效果显著优于胚毒灭活苗和活疫苗,在接种后各个时期所产生的抗体效价均显著高于其它两种疫苗(P<0.01),最高AGP效价可达4.8log2;胚苗的免疫效果虽然差于囊苗,但明显优于活疫苗,当活苗免疫组鸡血清中已无可测性抗体时,胚苗组仍具有1.0log2的AGP效价。在攻毒试验中,囊苗组鸡对IBDV标准毒、两株野毒株的攻击均100%地获得了保护;胚苗组也均可获得80%的保护,这两种由地方毒株所制备的疫苗均未呈现出对不同毒株抵抗性的不同,而活苗组对不同毒株的攻击则分别只有53.3%、40%和46.7%的保护率,呈现出一定的差异性。     

鸡马立克氏病三价疫苗的安全性及免疫效力研究

将MD三价疫苗以25000PFU／只的剂量颈部皮下接种1日龄SPF雏鸡，结果表明，疫苗的接种不影响鸡体重的增加；不引起鸡法氏囊、脾脏等组织器官发生MD组织病理学变化，对鸡安全无毒性。用SPF鸡评价MD三价疫苗的免疫效力，三批疫苗对RB1B超强毒株攻击的平均保护效力为95．99％，而且无论是用RB1B超强毒株还是用BJMDV-1血毒攻击，MD三价疫苗的保护效力明显高于HVT＋SB1二价疫苗及HVT冻干苗，好于CV1988疫苗；接种MD三价疫苗的4个品系的商品鸡群，抗RB1B超强毒株攻毒的平均保护效力为94．60％；在模拟MD强毒自然传染的试验中，MD三价疫苗的保护效力达到95．65％。上述效力试验的结果说明：MD三价疫苗的免疫接种可使鸡形成抗MD强毒攻击的坚强免疫力。     

NDV不同浓度接种鸡胚后的HA效价比较

鸡新城疫是一种急性高度接触性传染病,为危害鸡群的主要传染病之一.近年来,在生产上出现了高致病性的强毒株,甚至超强毒株,一旦发生,难于控制,往往出现极高的死亡率,给养鸡业带来毁灭性的打击.防制本病的有效方法是对鸡群进行免疫接种,常用的疫苗有弱毒疫苗和灭活疫苗.随着毒株毒力的加强,用弱毒疫苗免疫接种经常出现免疫失败或保护不完全的情况,常常要结合ND油乳剂灭活苗接种才能取得较好的效果.而在强毒力的灭活苗的生产中,目前仍主要采用鸡胚作为病毒的繁殖载体.因此,获得高效价的病毒液（尿囊液）是制苗的关键.试验对如何获得高效价的尿囊液,确定接种时种毒的最佳浓度及鸡胚尿囊液的最佳收集时间进行探讨.     

不同IBD灭活疫苗在1日龄SPF鸡上的免疫效果评价

为了评价市场上不同厂家IBD全病毒或亚单位灭活苗的免疫效果,本研究用4种商品化疫苗(A、B、C、D,A为IBD亚单位灭活联苗,B～D为IBD全病毒灭活联苗)免疫1日龄SPF鸡,并采用AGP抗体、ELISA抗体和攻毒保护指标进行评价。结果显示表明不同IBD灭活疫苗之间的免疫效果是存在差别的,D苗最好,C苗次之,A苗、B苗较差;IBD灭活疫苗所产生的ELISA抗体水平和AGP抗体水平与攻毒保护呈正相关,且ELISA抗体与AGP抗体产生趋势基本一致。     

鸡传染性法氏囊病活疫苗免疫效果评估

本试验选用A、B、C、D 4种商品化鸡传染性法氏囊病活疫苗免疫SPF鸡,进行攻毒试验以评估不同疫苗的免疫效果。10日龄SPF鸡分组后分别用A、B、C、D 4种商品化法氏囊病活疫苗按1羽份/只剂量接种免疫,21日龄时用1000 LD₅₀剂量的法氏囊超强毒株(GD0104)进行攻毒,各组疫苗的保护率分别为100%、85%、100%、100%;35日龄时用1000 LD₅₀剂量的法氏囊超强毒株(GD0104)进行攻毒,各组疫苗的保护率分别为100%、75%、95%、100%。免疫后抗体检测显示,抗体滴度水平D＞A＞C＞B,抗体转阳速度A＞D＞C＞B,免疫应激作用A、D＞B、C。综合考虑疫苗免疫攻毒后各项指标的变化,A、D疫苗免疫效果优于其他两种活疫苗,可以有效地为SPF鸡提供保护作用。     

鸡传染性法氏囊病疫苗对SPF鸡ND免疫效果的影响

通过免疫器官指数测定、IBD疫苗对ND免疫的效果影响以及IBD攻毒试验,对当前市场上常用IBD活疫苗进行免疫效力研究。结果显示A80、D78株毒力小,对法氏囊不造成损伤,对ND免疫无影响;B87株、KS96株毒力中等,对法氏囊有轻微的可恢复性损伤,对ND免疫影响较小;进口疫苗MB、2512株的毒力比较强,可以对法氏囊造成不可恢复性损伤,对ND免疫影响较大,有明显的抑制作用。IBDV强毒株攻毒后KS96株和MB株免疫组均有100%的保护率,其他疫苗也能达到60%以上的保护率。该研究为实际养殖中IBD疫苗的选择提供了实验数据和理论基础,具有一定的指导意义。     

鸡新城疫病毒的分离鉴定与交叉免疫保护试验

为了评价疫苗免疫保护效果,进而筛选出最佳的免疫方案,将分离到的鸡新城疫病毒(Newcas-tle disease virus,NDV)流行毒株制备成灭活疫苗进行交叉免疫保护试验研究。把采集到的疑似发生新城疫的病鸡肺、气管环等组织经处理后接种10日龄SPF鸡胚进行病毒的分离和增殖,并用血清学和分子生物学方法进行毒株的鉴定;用分离到的NDV/Chicken/TC/1/2011毒株制成油乳剂灭活苗,与La Sota疫苗以不同的疫苗组合免疫SPF鸡,进行交叉免疫保护试验。结果显示,共分离到9株新城疫病毒,其F蛋白裂解位点的氨基酸均为112 R-R-Q-K-R-F117,表现为强毒株的分子特征,与致病指数结果一致。分离株灭活苗组和分离株灭活苗+La Sota弱毒苗对试验鸡的免疫保护力最高,其次是La Sota灭活苗+La Sota弱毒苗和LaSota灭活苗,La Sota弱毒苗对试验鸡的免疫保护力最低。NDV分离株与疫苗株La Sota存在明显抗原性差异,这将对新城疫疫苗的发展和疾病控制策略制定至关重要。     

猪流行性腹泻病毒灭活疫苗的制备及攻毒保护研究

为研究现用猪流行性腹泻病毒(PEDV)CV777疫苗毒株对流行毒株的免疫保护效果,以RTPCR进行PEDV CV777疫苗株、JS12流行株S基因克隆测序,进行PEDV S基因核酸序列分析与氨基酸序列分析。分别以转瓶工艺与细胞悬浮培养工艺培养Vero E6细胞,制备PEDV CV777株转瓶灭活苗与悬浮灭活苗。分别以PEDV转瓶灭活苗、悬浮灭活苗、PEDV流行株组织灭活苗(JS12株)产前30d免疫经产母猪;母猪产仔后14d进行仔猪攻毒保护试验。核酸序列分析显示,PEDV CV777株S基因与流行毒株的相似性在96.4%~99.7%之间,氨基酸序列相似性在96.7%~99.5%之间。转瓶工艺制备PEDV抗原效价为107.0 TCID50/mL,悬浮培养制备PEDV抗原效价为108.5 TCID50/mL。攻毒保护试验显示,悬浮灭活苗免疫母猪后,仔猪有2/10发病,保护率为8/10,转瓶灭活苗组发病率为8/10,保护率仅为2/10;组织灭活苗组9/10发病;对照组10头全部发病。该试验证明,提高PEDV CV777株的抗原含量,能够有效提高疫苗对PEDV流行毒株的保护效果。     

日粮粗纤维水平对断乳力克斯兔营养物质消化率的影响

为探讨断乳兔日粮适宜的粗纤维水平,选择35日龄断乳的力克斯兔40只,随机分成A、B、C、D4组,每组10只,在等能等氮的基础上,分别饲喂粗纤维含量为7％、9％、12％和14％的日粮。研究表明：试验兔日增重分别为23．92±2．68g、25．23±2．49g、27．74±2．90g和25．70±3．37g,以C组最高,但差异不显著（P〉0．05）;平均料肉比分别为2．95：1、2．94：1、2．87：1和3．4：1,以C组最佳;平均日采食量分别为70．5g、74．26g、79．82g和87．38g,即随粗纤维含量的增加采食量递增（P〈0．05）;粗蛋白、粗脂肪、粗灰分和无氮浸出物的消化率以粗纤维为12％的C组最高,而且D组各养分的消化率均极显著地低于C组（P〈0．01）。但粗纤维水平由12％增加到14％,各种养分的消化率均下降,尤其是粗蛋白消化率的下降幅度达极显著水平（P〈0．01）。粗纤维的消化率随着日粮粗纤维含量的增加而降低;盲肠内容物各营养素的含量受日粮粗纤维水平的影响,与营养物质的消化率相吻合。本试验条件下,断乳兔日粮适宜的粗纤维水平为12％。     

鸡传染性法氏囊病活疫苗（B87株 CA株 CF株）安全性及免疫效果评价

通过观察疫苗免疫后鸡群的生长情况和临床症状,检测免疫后不同时期鸡群的ELISA抗体水平和攻毒保护率以及对鸡新城疫（ND）疫苗免疫后不同时间鸡群的HI抗体水平,评价和检测鸡传染性法氏囊病活疫苗（B87株 CA株 CF株）在石家庄地区临床应用的安全性、免疫效果、免疫持续期以及是否会产生免疫抑制。结果表明,试验疫苗接种蛋鸡和肉鸡后,均没有观察到因疫苗引起的不良反应,对蛋鸡和肉鸡均安全。疫苗接种蛋鸡后14 d、28 d、42 d、60 d和90 d,接种肉鸡后14 d、21 d、36 d攻毒保护率均达80%以上;商品蛋鸡接种疫苗后90 d其ELISA抗体水平仍高达6500以上。ND HI抗体检测结果表明,试验疫苗接种后对ND疫苗的免疫应答无显著影响,不引起免疫抑制。结论：试验疫苗安全、有效,质量稳定,适用于预防鸡传染性法氏囊病。     

五种市售鸡传染性鼻炎灭活疫苗免疫效力比较

本研究对国内市场上几个主要鸡传染性鼻炎灭活疫苗生产厂家生产的灭活疫苗免疫鸡只进行血清HI抗体水平测定和攻毒,比较不同公司所产疫苗效力的效力差异,并评估A、C型二价灭活疫苗两次免疫鸡群对国内B型分离株:DL-1株和最近从免疫失败鸡场分离到的SD-1株的交叉保护作用,分析免疫失败的原因.结果表明:A、D、E公司的疫苗免疫两次后,A型HI抗体阳性率分别为92.5%、100%和95%,滴度分别为33.9、55.1和59.9,攻毒保护率都是100%.C型HI抗体阳性率分别为72.5%、38.5%和77.5%,滴度分别为11.4、2.7和27,攻毒保护率分别为80%、70%和80%.而B和C公司的疫苗免疫两次后A型HI抗体阳性率分别为59.4%、77.1%,抗体滴度分别为5.4和21.8,攻毒保护率分别为50%和66.7%;C型HI抗体阳性率分别为54.1%和51.4%,抗体滴度分别为6.1和6.8,攻毒保护率分别为38.3%和50%.在五个疫苗产品中,以A、D、E的保护效力较好,B、C产品效力较差.另外,A、C型二价灭活疫苗免疫后不能对B型菌的攻击提供保护,其A、C型HI抗体阳性率、抗体滴度与对B型菌攻毒保护率无相关性.     

鸡大肠杆菌Ⅰ型菌毛亚单位苗交叉保护的初步研究

含Ⅰ型菌毛的３ 个不同血清型（Ｏ１ 、Ｏ７８ 及Ｏ８８） 的菌株， 大容量培养后提取菌毛制备３ 种单价菌毛油乳苗。用１ 日龄雏鸡分别免疫３ 种单价菌毛油乳剂苗， 每雏免疫量为１２５ μｇ ， 隔离饲养至２ 周龄经气囊攻毒， 并评价疫苗的免疫原性。结果未免疫鸡出现８７－５ ％ ～１００ ％ 的死亡率， 免疫鸡用同源菌株攻毒后死亡率仅１２－５ ％ ， 用异源菌株攻毒出现３７－５％ ～６２－５ ％ 的死亡率。免疫鸡攻毒后未死亡者， 经扑杀观察， 可见在气囊、心包及肝脏的病变非常轻微， 且攻毒后比非免疫鸡能更有效地清除攻入气囊的大肠杆菌     

Serological relationship of a Japanese Babesia species and Babesia bigemina by the complement fixation and capillary-tube agglutination tests

The complement fixation (CF) test and the capillary-tube agglutination (CA) test were used to study the antigenic relationship between Babesia bigemina and the large Babesia species frequently infecting cattle in Japan. The CF antigen was prepared from parasitized erythrocytes by extraction with distilled water. The CA antigen was prepared from parasitized erythrocytes by mild sonification of mixtures of Babesia and erythrocyte stroma, following lysis of the erythrocytes with hypotonic saline solution. All the sera used were collected from experimentally-infected cattle. Cross reaction was demonstrated between the Japanese Babesia species and B. bigemina. There was, however, a difference of two dilutions in titer between homologous and heterologous antibody in the CF test, and a difference of more than three tubes in titer between both antibodies in the CA test. It was possible, therefore, to distinguish the Japanese Babesia species from B. bigemina by the CF and CA tests.     

Comparative evaluation of commercial latex agglutination and coagglutination reagents for groups B, C, and D mastitis streptococci

A total of 144 strains of mastitis streptococci (groups B, C, and D) were grouped by conventional technique (Lancefield precipitin test) latex agglutination (LA), and coagglutination (CA). The LA correctly grouped 98% and the CA grouped 100% of strains on the test when the instructions of the manufacturers were followed. Sensitivity of both tests was improved for strains belonging to group D when extracts from colonies grown on sheep blood agar plates were used for grouping. Nonspecific reactions between groups C and B were observed only with one kit of LA reagents, whereas cross-reactions were recorded with all groups when CA reagents were used.     

The efficacy of recombinant fowlpox vaccine protection against Marek's disease: its dependence on chicken line and B haplotype

Earlier studies have shown that the B haplotype has a significant influence on the protective efficacy of vaccines against Marek's disease (MD) and that the level of protection varies dependent on the serotype of MD virus (MDV) used in the vaccine. To determine if the protective glycoprotein gene gB is a basis for this association, we compared recombinant fowlpox virus (rFPV) containing a single gB gene from three serotypes of MDV. The rFPV were used to vaccinate 15.B congenic lines. Nonvaccinated chickens from all three haplotypes had 84%-97% MD after challenge. The rFPV containing gB1 provides better protection than rFPV containing gB2 or gB3 in all three B genotypes. Moreover, the gB proteins were critical, since the B*21/*21 chickens had better protection than chickens with B*13/*13 or B*5/*5 using rFPV with gB1, gB2, or gB3. A newly described combined rFPV/gB1gEgIUL32 + HVT vaccine was analyzed in chickens of lines 15 x 7 (B*2/*15) and N (B*21/*21) challenged with two vv+ strains of MDV. There were line differences in protection by the vaccines and line N had better protection with the rFPV/gB1gEgIUL32 + HVT vaccines (92%-100%) following either MDV challenge, but protection was significantly lower in 15 X 7 chickens (35%) when compared with the vaccine CVI988/Rispens (94%) and 301B1 + HVT (65%). Another experiment used four lines of chickens receiving the new rFPV + HVT vaccine or CVI988/Rispens and challenge with 648A MDV. The CVI 988/Rispens generally provided better protection in lines P and 15 X 7 and in one replicate with line TK. The combined rFPV/gB1gEgIUL32 + HVT vaccines protected line N chickens (90%) better than did CVI988/Rispens (73%). These data indicate that rFPV + HVT vaccines may provide protection against MD that is equivalent to or superior to CVI988/ Rispens in some chicken strains. It is not clear whether the rFPV/gB1gEgIUL32 + HVT vaccine will offer high levels of protection to commercial strains, but this vaccine, when used in line N chickens, may be a useful model to study interactions between vaccines and chicken genotypes and may thereby improve future MD vaccines.     

Laboratory diagnosis of foot-and-mouth disease and swine vesicular disease in the years 1962-1988 in Greece]

During 26 years (1962-1988) 499 samples from FMD-suspicious cases were examined in Greece. These materials came from 348 (70%) cattle, 95 (19%) pigs and 56 (11%) sheep and goats. The cattle with 197 (72.4%) positive cases seems to play the most important roll in FMD. The different isolated virus types belonged in 60 cases to type A, in 187 to type O, in 14 to type C, in 6 to type SAT 1 and in 2 cases to type ASIA 1, respectively. SVD was isolated in 3 cases from the same area and at the same time. Most samples have been examined by means of CF, cell culture, unweaned mice or by a combined way of these assays. From 363 samples have examined: A) 148 by CF, B) 32 by CF and cell culture, C) 64 by CF and baby mice D) 80 by CF, cell culture baby mice E) 8 by cell culture, F) 18 in cell culture and baby mice and G) 13 by baby mice. Form these samples were found positive in the case A) 74 (50%), E) 3 (38%) and none in case G. On the other hand, the correlation of the positive samples in combined assays were in case B) 9:21, C) 9:1, D) 8:22:16 and the case F) 3:2 respectively. The D case shows that CF detected less positive cases than the cell culture did. For a reliable labor diagnosis of FMD every sample must be examined by more than one method.     

Evaluation of factors affecting vaccine efficacy of recombinant Marek's disease virus lacking the Meq oncogene in chickens

We previously reported that deletion of the Meq gene from the oncogenic rMd5 virus rendered it apathogenic for chickens. Here we examined multiple factors affecting Marek's disease vaccine efficacy of this nonpathogenic recombinant Meq null rMd5 virus (rMd5deltaMeq). These factors included host genetics (MHC haplotype), strain or dose of challenge virus, vaccine challenge intervals, and maternal antibody status of the vaccinated chicks. Studies on host genetics were carried out in five chicken lines comprising four different MHC B-haplotypes. Results showed that chicken lines tested were highly protected, with protective indexes of 100% (B*2/*15), 94% (B*2/*2), 87% (B*19/*19), and 83% (B*21/*21). At a challenge dose above 8000 plaque-forming units, differences in protection were observed between the two highly virulent strains examined (648A and 686). The interval between vaccination and challenge indicated a protective efficacy from 0 to 2 days varied greatly (12%-82%) after challenge with vv+686, the most virulent virus. Less variation and significant protection began at 3 days post vaccination and reached a maximum at 5 days post vaccination with about 80%-100% protection. Taken together, our results indicate that the factors examined in this study are important for vaccine efficacy and need to be considered in comparative evaluations of vaccines.